See more : Encore Wire Corporation (WIRE) Income Statement Analysis – Financial Results
Complete financial analysis of Concord Biotech Limited (CONCORDBIO.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concord Biotech Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Byggmax Group AB (publ) (BMAX.ST) Income Statement Analysis – Financial Results
- Anavex Life Sciences Corp. (AVXL) Income Statement Analysis – Financial Results
- China Infrastructure Investment Limited (0600.HK) Income Statement Analysis – Financial Results
- Uniinfo Telecom Services Limited (UNIINFO.NS) Income Statement Analysis – Financial Results
- MKB Nedsense NV (NEDSE.AS) Income Statement Analysis – Financial Results
Concord Biotech Limited (CONCORDBIO.NS)
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 9.98B | 8.53B | 7.08B | 6.04B | 5.12B |
| Cost of Revenue | 2.45B | 1.80B | 1.78B | 1.20B | 1.38B |
| Gross Profit | 7.53B | 6.73B | 5.31B | 4.84B | 3.74B |
| Gross Profit Ratio | 75.47% | 78.88% | 74.89% | 80.08% | 73.05% |
| Research & Development | 229.04M | 328.30M | 290.87M | 0.00 | 0.00 |
| General & Administrative | 111.29M | 105.02M | 105.81M | 70.94M | 63.01M |
| Selling & Marketing | 331.10M | 236.98M | 214.36M | 133.63M | 156.03M |
| SG&A | 1.23B | 342.00M | 320.17M | 204.57M | 219.04M |
| Other Expenses | 0.00 | 353.09M | 9.73M | 11.25M | 0.00 |
| Operating Expenses | 1.46B | 3.84B | 2.94B | 1.80B | 1.60B |
| Cost & Expenses | 3.91B | 5.64B | 4.72B | 3.01B | 2.98B |
| Interest Income | 30.41M | 44.41M | 47.87M | 17.87M | 760.00K |
| Interest Expense | 31.26M | 45.10M | 54.84M | 6.66M | 11.67M |
| Depreciation & Amortization | 535.92M | 540.32M | 500.50M | 275.23M | 200.53M |
| EBITDA | 4.66B | 3.83B | 2.97B | 3.42B | 2.14B |
| EBITDA Ratio | 46.68% | 44.61% | 41.50% | 55.36% | 41.78% |
| Operating Income | 6.26B | 3.27B | 2.44B | 3.07B | 1.94B |
| Operating Income Ratio | 62.74% | 38.27% | 34.44% | 50.80% | 37.87% |
| Total Other Income/Expenses | -2.14B | -1.96B | -1.75B | 94.68M | -981.89M |
| Income Before Tax | 4.13B | 3.22B | 2.38B | 3.13B | 2.14B |
| Income Before Tax Ratio | 41.34% | 37.74% | 33.53% | 51.77% | 41.70% |
| Income Tax Expense | 1.04B | 819.28M | 625.89M | 778.33M | 445.26M |
| Net Income | 3.08B | 2.40B | 1.75B | 2.35B | 1.69B |
| Net Income Ratio | 30.87% | 28.14% | 24.69% | 38.89% | 33.01% |
| EPS | 29.45 | 22.95 | 16.72 | 22.45 | 16.16 |
| EPS Diluted | 29.45 | 22.95 | 16.72 | 22.45 | 16.16 |
| Weighted Avg Shares Out | 104.62M | 104.62M | 104.62M | 104.62M | 104.62M |
| Weighted Avg Shares Out (Dil) | 104.62M | 104.62M | 104.62M | 104.62M | 104.62M |
Source: https://incomestatements.info
Category: Stock Reports